Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
DIRAS3 Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB, E |
|---|---|
| Primary Accession | O95661 |
| Other Accession | NP_004666, 4757772 |
| Reactivity | Human |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Calculated MW | Predicted: 25 kDa Observed: 24 kDa |
| Application Notes | DIRAS3 antibody can be used for detection of DIRAS3 by Western blot at 1 - 2 µg/ml. |
| Gene ID | 9077 |
|---|---|
| Target/Specificity | DIRAS3; DIRAS3 antibody is human specific. |
| Reconstitution & Storage | DIRAS3 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. |
| Precautions | DIRAS3 Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | DIRAS3 |
|---|---|
| Synonyms | ARHI, NOEY2, RHOI |
| Cellular Location | Cell membrane; Lipid-anchor; Cytoplasmic side |
| Tissue Location | Expressed in normal ovarian and breast epithelial cells but not in ovarian and breast cancers |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
DIRAS3 is a member of the ras superfamily, and is expressed in normal ovarian and breast epithelial cells, but not in ovarian and breast cancers. It is an imprinted gene, with mono-allelic expression of the paternal allele, which is associated with growth suppression and down-regulation of cyclin D1 promoter activity and induction of p21 (WAF/CIP1). Thus, this gene appears to be a putative tumor suppressor gene whose function is abrogated in ovarian and breast cancers (1). DIRAS3 has been shown to induce autophagy in human ovarian cancer cells by blocking PI3K signaling, inhibiting the mammalian target of rapamycin (TOR), upregulating ATG4, and colocalizing with LC3 in autophagosomes (2). DIRAS also interacts with C-RAF and downregulates mitogen-activated protein kinase kinases (MEK) to restrict cell migration (3).
References
Yu Y, Xu F, Peng H, et al. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc. Natl. Acad. Sci. USA 1999; 96:214-9.
Lu Z, Luo RZ, Lu Y, et al. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J. Clin. Invest. 2008; 118:3917-29.
Klingauf M, Beck M, Berge U, et al. The tumour suppressor DiRas3 interacts with C-RAF and downregulates MEK activity to restrict cell migration. Biol. Cell 2013; 105:91-107.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
